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(Not) warts aNd all
Government fully considered 
HPV vaccine
It was unfortunate that Hammond wrote his piece 
without asking us the government’s reasons 
for choosing the human papillomavirus (HPV) 
vaccine.1 We fully considered all of the issues 
he raised and much more that was scientific, 
logistic, and economic.
We used the cost effectiveness analysis of Jit 
et al to allocate points for the quality of scientific 
information on protection against cervical cancer, 
protection against warts, and stability out of 
the cold chain,2 and only after the scoring was 
completed were the prices revealed. With the 
same analysis,2 the prices were scored for cost 
effectiveness in balance with the other factors. 
The scoring system had been shared in advance 
with the manufacturers. In central contracts 
the price offered by manufacturers can differ 
considerably between products and against the 
list price.
We took full account of the burden of genital 
warts and the benefits that might come from 
vaccinating males. Perhaps Hammond might 
have asked himself how much he was prepared 
to pay to prevent genital warts; I assume that 
even he must have a figure in mind beyond 
which it would not be cost effective to use a 
quadrivalent vaccine.
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“Annoyance” of genital warts
As Hammond said,1 and my website shows in the 
wart section (www.chestersexualhealth.co.uk), 
genital warts are not just an annoying nuisance. 
Both human papillomavirus (HPV) vaccines are 
so far equally effective for HPV 16 and 18, but 
it will be many years before we know whether 
one has longer efficacy than the other. The 
Department of Health estimated the cost of wart 
treatment at an all time low of £134 per patient. 
The cost is around £423 per patient in my clinic, 
where even first visit payment by results is £153 
and follow-up £90; most warts need a few visits.
Despite GSK’s assertion of winning eligible 
contracts, I am not aware of any country that has 
chosen Cervarix as the national vaccine. Also, 
why won’t the Food and Drug Administration 
approve it? Has it concerns that the British don’t 
know about? Now that top- up payments are in 
the clear in the UK, can parents top up and buy 
Gardasil? The NHS price of both vaccines is £80 a 
shot, with three shots needed.
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All data on both vaccines  
must be considered
The government chose the human 
papillomavirus (HPV) vaccine of GlaxoSmithKline 
(GSK), Cervarix, after considering protection 
against cancer causing HPV 16 and 18, HPV 6 
and 11 (which cause genital warts), and HPV 
strains not included in the vaccine formulation; 
price; and supply.1
Its decision was based on a comprehensive 
review of published and unpublished clinical 
efficacy and safety data. New data from GSK 
included the demonstration of high protection 
against HPV 16 and 18 for over 6.4 years, the 
longest protection reported for any cervical 
cancer vaccine to date. The study is being 
extended for up to 9.5 years in a subset of 
women.
The UK has awarded a national licence, but 
in many other European countries licences 
are awarded regionally. Only once licensed 
in a country can a vaccine compete in tender 
applications. Gardasil was licensed in the 
European Union a year before Cervarix, and was, 
until recently, the only product available for this 
indication. Since it was licensed, Cervarix has 
been awarded around two thirds (27/42) of the 
competitive tenders submitted in the EU.
GSK’s application with the Food and Drug 
Administration (FDA) is progressing. GSK has 
submitted its response to questions raised by 
the FDA in the complete response letter, received 
in December 2007, and discussions continue 
to be positive and productive. Each regulatory 
agency operates independently. To date, Cervarix 
has been approved in 67 countries around the 
world, including the 27 member countries of 
the EU, Mexico, Australia, Singapore, and the 
Philippines.
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PreservatioN of fertility
uncertainties in preserving 
fertility in cancer treatment
Infertility is one of the more devastating long 
term effects of cancer treatment in young 
patients,1 but predicting who is at high risk 
of infertility is difficult. Patients often did not 
receive adequate information, but a recent 
prospective analysis of UK paediatric oncologists 
showed that risk to fertility was discussed with 
most children and adolescents at all ages, and 
with 76% and 86% of postpubertal boys and 
girls.2 Consequently 83% of postpubertal boys 
(the only group for whom an established method 
of fertility preservation is available) were referred 
to a fertility unit.
The constant development of chemotherapy 
regimens limits the ability of doctors to counsel 
patients accurately on the impact of a proposed 
treatment on fertility. This is important when 
fertility preservation requires significant 
intervention—for example, ovarian stimulation 
with oocyte/embryo cryopreservation, and 
laparoscopy to retrieve ovarian tissue. Our 
criteria for cryopreservation of ovarian cortical 
tissue include age <30 years and a high risk of 
treatment induced immediate ovarian failure 
in a patient with a realistic chance of long term 
survival.3 We have performed ovarian tissue 
cryopreservation in 36 women and girls with up 
to 13 years of follow-up.4 Seven have since had 
spontaneous pregnancies with five live births, 
and only two patients have ovarian failure.
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The uncertainty of preserving fertility must 
be conveyed to women considering an invasive 
procedure of unknown efficacy (only five babies 
have been born from this technique worldwide) 
at a time of high emotional vulnerability and 
acute, life threatening illness. The issues over 
consent for children to undergo this are even 
more complex.5
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Institute, Edinburgh Eh16 4TJ richard.anderson@ed.ac.uk 
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surgical site iNfectioN
Guidelines or misguidance?
The drive to minimise surgical wound infection 
should be an instinct instilled early into surgical 
trainees on the basis of surgical pride and 
the need to minimise harm to their patients. 
The more the process is devolved into sets of 
guidelines1 the less effective the outcomes will 
be, and the less personal responsibility will be 
taken by clinicians at all levels.
What is astonishing is that the guidelines by 
Leaper et al and the accompanying commentary 
do not mention any of the most important factors 
in wound infection—namely, the skill and training 
of the surgeon, and, most importantly, judgment, 
planning, and the avoidance of tissue damage 
and haematoma.1 2
I predict a continuing fruitless struggle to deal 
with wound infection that no amount of well-
meaning guidelines will solve while:
 Trainees’ hours are systematically reduced for • 
fear of the European Working Time  Directive
 There is no continuity, because of shift • 
systems, to allow trainees to follow up and 
deal with the clinical consequences of their 
actions
 Consultants are inhibited from forceful • 
condemnation of poor practice by fears of 
accusations over bullying or harrassment
 There is increasing micro-specialisation, • 
making it impossible for trainees to maintain a 
holistic view of treatment of patient rather than 
condition
Problems and responsibilities for • 
postoperative infection are devolved to less 
educated wound care specialists whose 
activity is rarely, if ever, audited
 Every aspect of medical and surgical care • 
is subject to guidelines and rules instead of 
allowing clinicians to think for themselves and 
take the fullest responsibility for their own 
actions.
Leaper et al simply cannot be allowed to get 
away with their suggestion that money should be 
thrown at the implementation of their document 
by “training adequate healthcare professionals.”1 
Unless of course they mean reverting to decent 
surgical education by apprenticeship.
Peter J Mahaffey consultant plastic and reconstructive surgeon, 
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does this work for you?
Individuals, averages, and 
evidence based medicine
In asking “Does this work for you?”1 Christakis 
finds the heart of evidence based medicine—
“the conscientious, explicit and judicious use 
of current best evidence in making decisions 
about the care of individual patients.”2 The 
individual approach can also reconcile clinical 
trial results with the demands of clinical 
practice: “managers and trialists may be happy 
for treatments to work on average; patients 
expect their doctors to do better than that.”3
That not all patients achieve great benefit 
and need an individualised approach has been 
shown in treating depression4 and is particularly 
true for pain.
In acute pain, patients either have very 
good or very poor pain relief with non-steroidal 
anti-inflammatory drugs. In neuropathic pain 
fewer than half of patients commonly achieve 
adequate pain relief with any treatment. In 
migraine the proportion of patients achieving 
rapid and prolonged pain relief (adjusted for 
the placebo response) is only about 25%. With 
TNF-antagonists in rheumatoid arthritis the 
proportion achieving a beneficial outcome after 
12 months is 60% for ACR20, 40% for ACR50, 
and 20% for ACR70. In osteoarthritis the 80-20 
rule applies, 80% of patients getting 20% pain 
relief, and 20% getting 80% pain relief; about 
half get half pain relief, a very good outcome.
Various solutions would make clinical trials 
more useful—for example, better reporting 
of conventional trial designs and use of 
enriched enrolment randomised withdrawal 
designs, especially when the proportion of 
patients experiencing benefit is low.5 Clinical 
effectiveness trials comparing different 
treatments and reporting a level of response 
that makes sound clinical sense would have 
immediate clinical impact, would underpin 
clinical decision making and guideline 
development, and may offer more relevant 
approaches to health economic assessment.
The individual patient approach is even 
more important in clinical practice, especially 
when few if any interventions produce high 
rates of good response. In difficult conditions 
such as neuropathic pain many interventions 
are needed to be able to achieve a good result 
for the patient we are treating. Restrictive 
formularies don’t help.
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PoPadad trial
Don’t stop taking aspirin
The POPADAD trial shows no benefit from daily 
prophylactic aspirin (hazard ratio 0.98; P=0.87) 
in people who have diabetes and early peripheral 
arterial disease. However, no firm conclusions 
should be drawn from a single trial, but the 
result be incorporated in a meta-analysis of all 
available evidence from relevant trials.1
The absence of evidence of benefit is 
not surprising as the trial was seriously 
underpowered. The annual cardiovascular event 
rate observed was only 2.9%, while the event 
rate expected was 8%. The 95% confidence 
limits for the effect of aspirin (0.76 to 1.26) 
include a possible 24% reduction in vascular 
events. This is consistent with the effect of 
aspirin in other trials of primary prevention. It 
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We agree that the event rate in the study was 
low—a testament to the efforts of the consultants 
to modify lipids and blood pressure optimally. 
We plan a subgroup analysis looking at the 
interactions with statins, as was predefined in 
our protocol.
Nevertheless, there may be a good reason for 
aspirin being ineffective in primary prevention 
in this population. With an atherothrombotic 
event, clot is formed and ruptured plaque is a 
huge stimulus for platelet aggregation. However, 
in primary prevention, where there has been 
no event, thrombus is not routinely formed. 
Statins and antihypertensive drugs are effective 
prophylaxis in primary prevention.2 3 Targeting 
vessel wall rather than thrombus, they might 
be expected to be more efficacious than an 
antiplatelet agent.
In contrast in secondary prevention, such as in 
CLIPS, aspirin has a role in preventing secondary 
events. This remains speculative, however, but 
there are a number of other trials in which aspirin 
as primary prevention, has been ineffective.1 4 We 
too await the results from ASCEND.
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cardiovascular Research, University of Dundee, ninewells 
hospital, Dundee DD1 9Sy j.j.f.belch@dundee.ac.uk
Competing interests: none declared.
Fleming T, Nissen SE, Borer JS, Armstrong PW. Report 1 
from the 100th cardiovascular and renal drugs advisory 
committee meeting: US Food and Drug Administration: 
December 8-9, 2003 Gaithersburg, MD. Circulation 
2004;109:e9004-5.
Shepherd J, Cobbe SM, Ford I, et al, for the West of 2 
Scotland Coronary Prevention Study Group. Prevention 
of coronary heart disease with pravastatin in men with 
hypercholesterolemia. N Engl J Med 1995;333:1301-7.
Dahlöf B, Sever PS, Poulter NR, for the ASCOT 3 
investigators. Prevention of cardiovascular events 
with an antihypertensive regimen of amlodipine 
adding perindopril as required versus atenolol adding 
bendroflumethiazide as required, in the Anglo-
Scandinavian cardiac outcomes trial-blood pressure 
lowering arm (ASCOT-BPLA): a multicentre randomised 
controlled trial. Lancet 2005;366:895-906.
Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, 4 
Manson JE, et al. A randomized trial of low-dose aspirin 
in the primary prevention of cardiovascular disease in 
women. N Engl J Med 2005;352:1293-304.
Cite this as: BMJ 2008;337:a2582
Time for a proper study of 
aspirin after a vascular event?
Belch et al add to the documentation that long 
term aspirin has little or no benefit in patients 
who have or are at risk of atherosclerotic 
cardiovascular disease.1 2
Few long term trials of aspirin have shown 
a reduction in mortality or major morbidity. 
However, editors of journals persist in publishing 
papers on aspirin with conclusions designed to 
mislead health professionals and the public.
The New England Journal of Medicine must 
take first place in this rogue’s gallery with 
publication of the US physician’s study (stopped 
for futility but published as a positive trial after 
retrospective rearrangement of the primary end 
point).3 Then comes the Lancet with the HOT 
study, which recommended aspirin despite the 
study being neutral on its primary end point 
and retrospectively redefining the criteria for 
myocardial infarction.4 And again with the PEP 
study, which showed a significant excess of 
fatal and non-fatal myocardial infarction when 
aspirin was used for prophylaxis of deep venous 
thrombosis after hip fracture but this worrying 
finding was not highlighted in the conclusions.5
The shortcomings of the aspirin meta-analysis 
have not been well publicised, although the BMJ 
has not stifled the debate totally.2 However, Belch 
and colleagues’ conclusion—“aspirin should, 
however, still be given for secondary prevention 
of cardiovascular disease in people with diabetes 
mellitus, when the evidence base is convincing, 
and the results of this study must not detract from 
this important standard of care”—should have 
specified the duration of aspirin prophylaxis after 
a vascular event for which there is evidence of 
benefit (about 6-12 weeks). There is no evidence 
of a longer term benefit with aspirin and some 
concern that there may be harm.
We should assess aspirin in the same way as 
any other therapeutic intervention. No trial shows 
that contemporary doses of aspirin used long term 
reduce mortality. Is it not time for an adequately 
powered study comparing short with long term 
aspirin 75mg/day after a vascular event?
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prophylaxis was associated with a significant 
reduction in vascular events (P=0.01).2
Belch and colleagues suggest that statins 
may have led to the low vascular event rate 
during the trial, giving little opportunity for the 
detection of additional benefit from the aspirin. 
This important hypothesis requires testing, the 
authors giving no data on a possible interaction 
between aspirin and statins.
The life threatening consequences of 
diabetes—mainly heart disease and stroke—are 
at least twice as frequent in people with diabetes 
as in those without. Guidelines issued by 
expert bodies in the United Kingdom and in the 
United States therefore recommend low dose 
aspirin prophylaxis in people with diabetes.3 4 
Against this background, and in view of the 
evidence of benefit in other trials it would be 
most unfortunate if the results of POPADAD were 
to lead diabetic patients discontinuing aspirin 
prophylaxis. At the very least, the results of yet 
another large trial in diabetic subjects, ASCEND, 
should be awaited.
In due course appropriate overviews may 
ensure that recommendations about aspirin 
prophylaxis in diabetic patients will be 
consistent.5 In the meantime older diabetic 
patients should keep taking daily low dose 
aspirin.
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Author’s reply
We support Elwood’s suggestion to include our 
study in a meta-analysis of all aspirin primary 
prevention studies. We believe this may already 
be in draft form, but such an analysis, albeit 
without POPADAD, yielded negative results.1
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shared electroNic records
What have we really learnt?
Greenhalgh and colleagues see the shared 
electronic record as having to respond to existing 
ways of working and established practices, not 
the other way round.1 My take is this:
Powerful forces in established ways of working • 
in the NHS are hostile to technological 
changes that threaten established and 
possibly dysfunctional and wasteful practices. 
As a taxpayer, this is not acceptable, 
especially when we need to explore better 
ways of using tax revenues when times are 
likely to be hard
The scale of complex IT projects empowers • 
dissident critics to feed political interest in 
their failings. That these projects frequently 
focus on purely internal (to the NHS) goals 
and objectives makes them largely inscrutable 
with respect to benefits that may accrue to 
patients and their failure more damaging 
as there are no milestones for delivering 
taxpayer value. It is better to think of flexible, 
networked, and distributed approaches—a 
school of fish adjusting easily to changes in 
its environment versus a supertanker that is 
much harder to control. Politicians would be 
better responding to the benefits that large 
scale IT projects bring to the public than to 
internal NHS efficiencies that may result
Introducing new technologies must have • 
some consequences, and these are not 
necessarily helped by protecting incumbents 
and legacy systems from threat.
The lack of a patient held smart card for 
health, for instance, maintains the control of 
information in the hands of the clinicians and 
the provider infrastructure. Giving patients 
complete and total ownership of their health 
record is a critical way of driving quality 
improvement.
My fear is that the sunk costs are already 
so great that a rethink is unthinkable and that 
we cannot cut our losses and start again. In 
politics this would be a U turn, requiring another 
innovation called courage.
Michael Tremblay health technology and innovation policy 
adviser, Brabourne lees, ashford, Kent Tn25 6RJ  
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Disruptiveness of Google Health
Such is the pace of modern technology that the 
paper by Greenhalgh and colleagues is already 
out of date.1 They did not mention the launch of 
Google’s web based personal health record on 
20 May 2008 or the collapse of the NHS records 
system.2
Web 2.0 technology will no doubt disrupt the 
grand aspirations of the NHS IT project. Techno-
savvy patients using Google style applications 
might soon ask doctors to access their personal 
health records on the web.
Like the music industry, the NHS seems to 
have become self importantly complacent. We 
are deluding ourselves if we think that “the world 
is waiting to see” how the NHS IT programme 
unfolds. The world has already seen that, six 
years into the programme, NPfIT is overbudget 
and behind schedule. The NHS isn’t the global 
gold standard. Instead, it is a hugely wasteful, 
inefficient, and bloated monopoly that needs 
some serious competition. Did record companies 
ever imagine that one day music could be 
downloaded for free?
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MaNdatory flu vacciNatioN
Patient care drives mandatory 
vaccination
Both sides debating mandatory flu vaccination 
for healthcare workers canvass central 
arguments,1 2 but key issues require further 
exploration. Neither side acknowledged 
that health care differs fundamentally from 
other work. Its primary aim is not individual 
protection but protection of patients by reducing 
nosocomial flu. John Stuart Mills would support, 
not oppose, a mandatory programme.2
The autonomy argument focuses on individual 
rights of healthcare workers, ignoring the rights of 
others. Ethical assessment requires us to balance 
competing rights, and should include a patient’s 
right to a safe healthcare environment. Australian 
States and Territories already require hepatitis B 
vaccination for those who are not immune and 
provide patient care. Individual autonomy is not 
catered for, with healthcare workers exercising 
their right to choose more fundamentally: either 
work in health care and minimise the risk of 
infecting patients or work elsewhere.
Increasing flu vaccine coverage among 
healthcare workers is possible using incentives 
and signed declination, but results are better1 
and cost less to implement with mandatory 
requirements. Better coverage at a lower price 
makes a mandatory programme dominant in 
health economic terms before consideration of 
improved outcomes.
Most developed industrialised countries have 
workplace health and safety laws that require 
workers to be “free from risk of death, injury 
or illness caused by any workplace.”3 Flu is an 
annual and predictable workplace danger that 
universal vaccination of healthcare workers can 
reduce. How can mandatory programmes not be 
required under such laws?
Given that vaccinating eight healthcare 
workers can prevent the death of one patient,4 
how can healthcare workers continue to oppose 
mandatory flu vaccination?
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Scandinavian solution
I recently started work in Sweden after a UK 
medical education and several years working in 
the NHS.
I find the Swedish solution of introductions 
very appealing: completely do away with titles 
and address everyone by their first and second 
names.1 So my badge says “Alison Godbolt, 
doctor,” and that’s how I introduce myself.
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